The TLR9 ligand CpG ODN 2006 is a poor adjuvant for the induction of de novo CD8⁺ T-cell responses in vitro.

ABSTRACT: Toll-like receptor 9 (TLR9) agonists have gained traction in recent years as potential adjuvants for the induction of adaptive immune responses. It has nonetheless remained unclear to what extent such ligands can facilitate the priming events that generate antigen-specific effector and/or memory CD8⁺ T-cell populations. We used an established in vitro model to prime naive precursors from human peripheral blood mononuclear cells in the presence of various adjuvants, including CpG ODN 2006, a synthetic oligonucleotide TLR9 ligand (TLR9L). Unexpectedly, we found that TLR9L induced a suboptimal inflammatory milieu and promoted the antigen-driven expansion and functional maturation of naive CD8⁺ T cells ineffectively compared with either ssRNA40 or 2'3'-cGAMP, which activate other pattern recognition receptors (PRRs). TLR9L also inhibited the priming efficacy of 2'3'-cGAMP. Collectively, these results suggest that TLR9L is unlikely to be a good candidate for the optimal induction of de novo CD8⁺ T-cell responses, in contrast to adjuvants that operate via discrete PRRs.

SUBMITTER: Papagno L 

PROVIDER: S-EPMC7363897 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature